MONDE-NISSIN
26.5.2021 04:53:09 CEST | Business Wire | Press release
Monde Nissin Corporation (“Monde Nissin” or the “Company”) today announced that it completed the offering period for its proposed initial public offering (“IPO”) of 3,600,000,000 Common Shares (the “Offering”) at a price of Php13.50 per share, with an overallotment option of a further 540,000,000 Common Shares granted by the Selling Shareholder.
The Offering received overwhelming interest from global institutional investors and long-only funds, as well as strong demand from Philippines-based investors, resulting in an international and domestic book building process that was multiple times oversubscribed.
The IPO is the largest ever on the Philippines Stock Exchange (“PSE”) and the largest food and beverage IPO in Southeast Asia. It raises Php48.6 billion for Monde Nissin, excluding underwriting commissions and other offering expenses payable by the Company. The new international and domestic investors join the previously announced 11 renowned, global long-term cornerstone investors in making up Monde Nissin’s initial shareholder base.
“The extraordinary level of interest that we received from a broad range of international and domestic investors is a testament to the world-class company that we have built and the significant growth opportunities that lie ahead,” said Henry Soesanto, Chief Executive Officer of Monde Nissin Corporation.
Mr. Soesanto added, “Our Quorn and Asia-Pacific Branded Food and Beverage businesses are a powerful combination to advance our mission of food safety and food security. Quorn is a leading player in the fast-growing global meat alternatives segment with a loyal customer following and a defining set of healthy sustainable products. Our Asia-Pacific Branded Food and Beverage business is widely recognized for its leadership positions across each of its core segments. We intend to stay ahead of consumer demands through innovation and investment in technology to provide healthier and more delicious food.”
Mr. Soesanto concluded by saying, “The scale and timing of our IPO has only been made possible through the hard work and guidance of the dedicated teams at the Philippine Securities and Exchange Commission and the PSE, to whom I extend my sincere gratitude and thanks.”
Monde Nissin expects to commence trading on the PSE under the ticker symbol “MONDE” on June 1, 2021. Mr. Soesanto and guests plan to ring the opening bell.
As previously announced, the Company intends to use the net proceeds from the primary offer to fund capital expenditures, redeem the Arran Convertible Note and repay loans to commercial banks. A copy of Monde Nissin’s final prospectus is available on the Company’s website at https://mondenissin.com/company-prospectus/ .
UBS AG Singapore Branch, Citigroup Global Markets Limited and J.P. Morgan Securities plc served as Joint Global Coordinators and Joint Bookrunners for the offering. BDO Capital & Investment Corporation, BPI Capital Corporation and First Metro Investment Corporation were the Local Lead Underwriters and Joint Bookrunners. Credit Suisse (Singapore) Limited served as the Joint International Bookrunner. Macquarie Capital Securities (Singapore) Pte. Limited and Jefferies Singapore Limited served as the International Co-Bookrunners. China Bank Capital Corporation, PNB Capital and Investment Corporation and SB Capital Investment Corp. were the Domestic Co-Lead Underwriters.
This communication is not for distribution, directly or indirectly, in or into the United States (including is territories and possessions, any State of the United States and the District of Columbia). This communication is not an offer and does not form a part of any offer of securities for sale in the United States or elsewhere. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933 (the Securities Act), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No money, securities or other consideration is being solicited by this communication or the information contained herein and, if sent in response to this communication or the information contained herein, will not be accepted.
About Monde Nissin
Monde Nissin Corporation is a global food and beverages company headquartered in the Philippines, with a portfolio of iconic and market leading brands across fast-growing categories, including Lucky Me! noodles, SkyFlakes crackers, Fita crackers, Monde baked goods and Quorn meat alternative products. The Company aspires to improve the well-being of people and the planet, and create sustainable solutions for food security. That aspiration is reflected in our commitment to continuously improve our products to make them more delicious, nutritious, and better for the planet. For more information, please visit www.mondenissin.com .
About Quorn
Quorn Foods is a global market leader in healthy, sustainable protein. Headquartered in Stokesley, North Yorkshire in the United Kingdom, the company offers a wide range of great-tasting products to appeal to the rapidly expanding group of people wanting to reduce their meat consumption. The company employs around 900 people and exports to 15 countries around the world, including Australia, Singapore and the United States. Quorn® is one of the United Kingdom’s top 40 FMCG brands. Quorn Foods Ltd is the reporting group which includes a main trading company, Marlow Foods Ltd. Quorn Foods Ltd encompasses all international operations of Quorn® and Cauldron®. For more information, please visit www.quorn.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525006050/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
